Pralatrexate (Folotyn) — Clinical FAQs

Question 1

What is Pralatrexate FDA-approved to treat?

Accepted Answer

Pralatrexate is FDA-approved for the following oncology indications: 1. Relapsed or refractory peripheral T-cell lymphoma (PTCL) — single-agent therapy (FDA approved September 24, 2009; first drug specifically approved for PTCL; accelerated approval based on overall response rate from the PROPEL trial).

Question 2

How does Pralatrexate work (mechanism of action)?

Accepted Answer

Pralatrexate is a next-generation antifolate and dihydrofolate reductase (DHFR) inhibitor rationally designed with high affinity for reduced folate carrier-1 (RFC-1), the primary active transporter responsible for intracellular antifolate uptake. Compared with methotrexate, pralatrexate exhibits approximately 10-fold greater internalization via RFC-1, driven by its 10-propargyl group, which also confers superior polyglutamation by folylpolyglutamate synthetase (FPGS). Intracellularly retained polyglutamated pralatrexate potently inhibits DHFR and thymidylate synthase, disrupting de novo thymidylate and purine synthesis and ultimately blocking DNA replication. T-cell lymphomas overexpress RFC-1 relative to normal lymphocytes, providing the pharmacologic rationale for preferential activity in T-cell malignancies. Cell death occurs primarily during S-phase (cell-cycle specific).

Question 3

How is Pralatrexate administered?

Accepted Answer

Pralatrexate is administered Intravenous (IV). Administer pralatrexate 30 mg/m² as an undiluted IV push over 3-5 minutes (do not dilute; use 20 mg/mL solution directly) into a free-flowing IV line of 0.

Question 4

What are the most common side effects of Pralatrexate?

Accepted Answer

The most commonly reported side effects of Pralatrexate (≥10% incidence) include: Mucositis / oral mucositis / stomatitis (70%; Grade 3/4 ~17% — primary dose-limiting toxicity), Thrombocytopenia (41%; Grade 3/4 ~33%), Nausea (40%), Fatigue (36%), Anemia (34%; Grade 3/4 ~18%) and others (17 total). Consult your oncologist for complete prescribing information.

Question 5

Is Pralatrexate safe during pregnancy?

Accepted Answer

Pralatrexate pregnancy safety: Can cause fetal harm; pralatrexate is an antifolate and antifolate-class drugs are established teratogens and abortifacients. Females of reproductive potential should use effective contraception during treatment and for at least 6 months after the last dose. Males with female partners of reproductive potential should use contraception during treatment and for at least 3 months after the last dose. Not recommended during breastfeeding.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

Pralatrexate — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms